Drugs /

iberdomide

Back to Drugs List

Overview

NCI Definition [1]:
A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration CC-220 specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.

Clinical Trials

View Clinical Trials for iberdomide

Iberdomide has been investigated in 7 clinical trials, of which 7 are open and 0 are closed. Of the trials investigating iberdomide, 2 are phase 1 (2 open), 4 are phase 1/phase 2 (4 open), and 1 is phase 2 (1 open).

BCL2 Fusion, BCL6 Fusion, and EBV Positive are the most frequent biomarker inclusion criteria for iberdomide clinical trials.

B-cell non-hodgkin lymphoma, diffuse large B-cell lymphoma, and diffuse large B-cell lymphoma, not otherwise specified are the most common diseases being investigated in iberdomide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Iberdomide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating iberdomide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cc 220, cc-220, (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, crl4(crbn) e3 ubiquitin ligase modulator cc-220
NCIT ID [1]:
C129048

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.